Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | METAP1 | P53582 | 3/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866434 | 1.00 | ACHE (1.00) | ACHETSHRMETAP1CYP19A1NOS3 | |
| SCHEMBL9752693 | 1.00 | ACHE (1.00) | ACHETSHRMETAP1CYP19A1NOS3 | |
| SCHEMBL4938272 | 1.00 | ACHE (1.00) | ACHETSHRMETAP1CYP19A1NOS3 | |
| Hydrochloric Acid SCHEMBL7403735 | 0.98 | ACHE (0.96) | ACHETSHRMETAP1CYP19A1 | |
| Dimethylamine SCHEMBL8159682 | 0.92 | ACHE (0.85) | ACHETSHRMETAP1CYP19A1 | |
| SCHEMBL25001243 | 0.79 | ACHE (0.66) | ACHETSHRCYP19A1 | |
| SCHEMBL12676173 | 0.79 | ACHE (0.66) | ACHETSHRCYP19A1 | |
| SCHEMBL677613 | 0.79 | ACHE (0.66) | ACHETSHRCYP19A1 | |
| SCHEMBL10000875 | 0.79 | ACHE (0.66) | ACHETSHRCYP19A1 | |
| SCHEMBL3054005 | 0.79 | ACHE (0.66) | ACHETSHRMETAP1CYP19A1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861113-B | Preparation and application of fused ring pyridine compound and derivative thereof | 中国科学院福建物质结构研究所 | 2022-12-06 | — | — | CN | claimed |
| CN-115124878-A | Method for manufacturing rubber rain shoes with chameleon effect | 杭州星发彩印有限公司 | 2022-09-30 | — | — | CN | claimed |
| WO-2009149906-A2 | PREPARATION OF SILOXY-BRIDGED METALLOCENES | BASELL POLYOLEFINE GMBH (DE) | 2009-12-17 | — | — | WO | claimed |
| US-7544825-B1 | Preparation of siloxy-bridged metallocenes | BASELL POLYOLEFINE GMBH (DE) | 2009-06-09 | — | — | US | claimed |
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2007-07-26 | — | — | US | claimed |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2005-09-22 | — | — | US | claimed |
| US-20040077694-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2004-04-22 | — | — | US | claimed |
| US-6664291-B2 | Aromatic amidealkyl acid or ester or amide or hydroxy derivatives are useful in the treatment of obesity, overweight condition, hyperlipidemia, glucoma, cardiac arrhythmias, thyroid disease, skin disoders and diabetes | PFIZER, INC. | 2003-12-16 | — | — | US | claimed |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. | 2001-12-13 | — | — | US | claimed |
| US-5618982-A | SIMPLE INDUSTRIAL PROCESS OF CATALYZING IN PRESENCE OF METALLIC PHOSPHATES | RHONE-POULENC CHIMIE (FR) | 1997-04-08 | — | — | US | claimed |
| US-12564551-B2 | Composition or oat extract comprising avenanthramide and β-glucan | SYMRISE AG (DE) | 2026-03-03 | — | — | US | disclosed |
| EP-4013738-B1 | PROCESS FOR PREPARING 1-INDANONE COMPOUNDS BY INTRAMOLECULAR FRIEDEL-CRAFTS REACTION OF ALPHA,ALPHA-DIALKYLMALONATE DERIVATIVES | FIRMENICH & CIE (CH) | 2026-02-25 | — | — | EP | disclosed |
| US-12497359-B2 | Acrylamide derivatives | NRG THERAPEUTICS LTD (GB) | 2025-12-16 | — | — | US | disclosed |
| US-20250360486-A1 | Biorefining Method | LICELLA PTY LTD (AU) | 2025-11-27 | — | — | US | disclosed |
| US-12409437-B2 | Biorefining method | LICELLA PTY LTD (AU) | 2025-09-09 | — | — | US | disclosed |
| US-4076726-A | Amidino-hydrazone derivatives | AKZONA INCORPORATED (US) | 1978-02-28 | — | — | US | disclosed |
| US-4030994-A | FLUOROXY PENTAFLUOROSULFUR | MERCK & CO., INC. (US) | 1977-06-21 | — | — | US | disclosed |
| US-3985729-A | ANTIINFLAMMATORY AGENTS; CYCLIZATION OF 3-BENZYLAMINO-ALKYL-INDAN-1-OLS | SANDOZ, INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3976634-A | ANTIINFLAMMATORY | SANDOZ, INC. (US) | 1976-08-24 | — | — | US | disclosed |
| US-3956363-A | Substituted indenyl acetic acids | MERCK & CO., INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564551-B2 | Composition or oat extract comprising avenanthramide and β-glucan | CUTA, HLA-A, OAT | ACHE 1387/4885TSHR 1845/4885METAP1 661/4885 |
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | ACHE 975/4885TSHR 3/4885METAP1 2239/4885 |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | ACHE 975/4885TSHR 3/4885METAP1 2239/4885 |
| US-12497359-B2 | Acrylamide derivatives | ACR, GSTA2, GSTA1 | ACHE 963/4885TSHR 4067/4885METAP1 3832/4885 |
| US-20040077694-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | ACHE 1095/4885TSHR 3/4885METAP1 2061/4885 |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, THRB | ACHE 1217/4885TSHR 4/4885METAP1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.